Hemophilia a bone health under the microscope: which treatment wins?
NCT ID NCT07582276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 50 men with severe hemophilia A for five years to compare bone density between those taking emicizumab and those taking efanesoctocog alfa. Researchers will also measure bone remodeling markers and joint health. The goal is to see if one treatment is linked to better bone outcomes, which could help doctors choose the best therapy for long-term bone health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emicizumab or efanesoctocog alfa
What this could lead to
If successful, this study could show which hemophilia A treatment better protects bone health, potentially guiding future therapy choices.
What could go wrong
This is an observational study, not a treatment trial. It only measures bone changes, so it won't directly improve health. Results may take years and might not lead to clear conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••